Log In
BCIQ
Print this Print this
 

SH7139

  Manage Alerts
Collapse Summary General Information
Company SHAL Technologies Inc.
DescriptionSelective high affinity ligand targeting HLA-DR10
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today